This review provides an overview of key aspects of the clinical use of trastuzumab deruxtecan (Enhertu®) and summaries of key clinical studies of its efficacy and tolerability in previously treated patients with unresectable or metastatic HER2-positive breast cancer. From 1st January 2025, trastuzumab deruxtecan is funded for eligible individuals who have metastatic breast cancer that has: i) progressed after prior trastuzumab treatment for metastatic disease; or ii) progressed within 6 months of adjuvant HER2-targeted treatment. This review is sponsored by AstraZeneca.
Please login below to download this issue (PDF)